Conference Coverage
Conference Coverage
ASH: Carfilzomib doubles progression free survival in head-to-head trial with bortezomib
Progression-free-survival was 18.7 months with carfilzomib compared with 9.4 months with bortezomib for patients with multiple myeloma.
Conference Coverage
ACR: Cryoglobulinemic vasculitis in Sjögren’s linked to lymphoma, mortality
Key clinical point: Cryoglobulinemic vasculitis increases the risk of B-cell lymphoma and death in patients with primary Sjögren’s syndrome. Major...
Conference Coverage
Multiple myeloma advances will be a hot topic at ASH
Conference Coverage
AHA: Older breast cancer patients more likely to die of heart disease than malignancy
Among women diagnosed with breast cancer in their 70s, more will die from cardiovascular disease than from their malignancy.
Conference Coverage
ACR: Years of TNF blockers did not increase risk of lymphoma in RA
Exposure to biological disease-modifying antirheumatic drugs did not increase the overall risk of lymphoma among patients with rheumatoid...
Conference Coverage
Hold the checkpoint inhibitors when pneumonitis symptoms occur
Key clinical point: Pneumonitis is an uncommon but potentially serious adverse event associated with PD-1/PD-L1 checkpoint inhibitor therapy....
Conference Coverage
Antibody drug conjugate induces responses in heavily pretreated TNBC
Key clinical point: Conjugating a metabolite of irinotecan to an antibody allows targeted delivery of the otherwise highly toxic drug. Major...
Conference Coverage
Immune-related events with checkpoint inhibitors are manageable
Key clinical point: Inhibitors of CTLA-4 and PD-1/PD-L1 are associated with manageable immune-related adverse events. Major finding: Cutaneous...
Conference Coverage
Elevated liver cancer risk after HCV cure may justify surveillance
Sustained virologic response in patients with well controlled hepatic C virus infection does not protect select subgroups of this cohort from...
Conference Coverage
High SVR achieved in decompensated HCV patients with 12-week therapy
The findings are encouraging because current treatment options for patients with HCV who have decompensated liver disease are limited, Dr....